Optimization of small-cell lung cancer chemotherapy with heparin: A comprehensive retrospective study of 239 patients treated in a single specialized center

Chemotherapy

Volumn 57, Issue 3, 2011, Pages 253-258

  Lebeau, Bernard ^a   Baud, Mariette ^a   Masanes, Marie José ^a   Febvre, Michel ^a   Mokhtari, Tarik ^a   Chouaïd, Christos ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Chemotherapy; Heparin; Radiotherapy; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEPARIN;

ADRENAL METASTASIS; ADULT; APLASIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG FATALITY; DRUG FEVER; FEBRILE APLASIA; FEMALE; GROUPS BY AGE; HEPARINIZATION; HUMAN; LIVER METASTASIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HEPARIN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 79957963171     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000328014     Document Type: Article

References (29)

1. Ihde DC: Small cell lung cancer. State-of-the-art therapy. Chest 1995;107:243S-248S.
2. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624.
3. Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-484. (Pubitemid 29372887)
4. Lebeau B, Chastang C, Bréchot JM, et al: Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994;74:38-45. (Pubitemid 24187607)
5. Jänne PA, Freidlin B, Saxman S, et al: Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Meaningful improvements in survival. Cancer 2002;95:1528-1538.
6. Aisner J: Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 1996;14:658-665. (Pubitemid 26051034)
7. Chelis L, Xenidis N, Amarantidis K, Prassopoulos P, Chamalidou E, Neanidis K, Mikroulis D, Chatzaki E, Karakitsos P, Kakolyris S: Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer. Chemotherapy 2010;56:353-358.
8. Komuta K, Osaki T, Mori M, Yokota S, Yoshiro T: Phase II study directed by a clinical pathway for carboplatin and weekly pacli-taxel in previously untreated patients with unresectable non-small cell lung cancer. Chemotherapy 2010;56:353-358.
9. Postmus EP: Second-line for small cell lung cancer: how to do it? Lung Cancer 2005;48:263-265.
10. Arpin D, Lasset C, Chauvin F, et al: Comparison between patients included in or excluded from clinical trials for small cell lung cancer. Lung Cancer 1991;11(suppl 1):103.
11. Lebeau B, Urban T, Bréchot JM, et al: A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. Cancer 1999;86:1480-1487. (Pubitemid 29489781)
12. Urban T, Chastang Cl, Lebas FX, et al: The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma. A randomised study of 457 patients. Cancer 1999;86:2238-2245. (Pubitemid 30010363)
13. Altinbas M, Coskun HS, Er O, et al: A randomised clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271. (Pubitemid 40186120)
14. Lebeau B, Chastang Cl, Schuller MP, et al: Chemotherapy in small cell lung carcinoma. Prognostic value of complete response in 1280 patients (French). Presse Med 1995;24:217-221.
15. Zacharski LR, Costantini V, Wojtukiewicz MZ, et al: Anticoagulants as cancer therapy. Semin Oncol 1990;17:217-227. (Pubitemid 20131812)
16. Kuderer NM, Khorana AA, Lyman GH, et al: A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. Cancer 2007;110:1149-1161. (Pubitemid 47312882)
17. Borsig L, Wong R, Feramisco J, et al: Hepa rin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins and tumor metastasis. Proc Natl Acad Sci USA 2001;98:3352-3357. (Pubitemid 32220849)
18. Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-1852. (Pubitemid 23360484)
19. Pujol JL, Carestia L, Daurès JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15.
20. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxoru-bicin, and vincristine versus cisplatin and etoposide versus alternation of these regimen sin smallcelllung cancer. J Natl Cancer Inst 1991;83:855-861.
21. Sundstrom S, Bremnes RM, Kaasa S, et al: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vin-cristine regimen in small-cell lung cancer: results from a randomised phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672. (Pubitemid 36025283)
22. Pujol JL, Daures JP, Rivière A, et al: Etopo-side plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300-308. (Pubitemid 32219817)
23. Groen H, Fokkema E, Biesma B, et al: Pacli-taxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etopo-side: a non-cross-resistant schedule. J Clin Oncol 1999;17:927-932. (Pubitemid 29109325)
24. O'Brien MER, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topote-can in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447. (Pubitemid 46623178)
25. Lebeau B, Chouaïd C, Baud M, et al: Oral second and third-line lomustine-etoposide-cy-clophosphamide chemotherapy for small cell lung cancer. Lung Cancer 2010;67:188-193.
26. de Jong WK, ten Hacken NHT, Groen HJM: Third-line chemotherapy for small cell lung cancer. Lung Cancer 2006;52:339-342. (Pubitemid 43674543)
27. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24:1057-1063. (Pubitemid 46638802)
28. Lebeau B, Chastang C, Bréchot JM, et al: A randomised trial of delayed radiotherapy in complete responder patients with small-cell lung cancer. Chest 1993;104:726-733. (Pubitemid 23268940)
29. Klerk CPW, Smorenburg SM, Otten HM, et al: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135. (Pubitemid 46218704)